OrthoCor Advanced Trial for Knee Osteoarthritis

December 16, 2025 updated by: Caerus Corporation

Prospective Trial of the OrthoCor Advanced System for Patients With Knee Osteoarthritis

The objective of this clinical trial is to show that PEMF therapy, heat, recovery metrics, and compliance data provided by the OrthoCor Advanced System improves pain and quality of life for patients with osteoarthritis. The main question it aims to answer is:

Does therapy from the OrthoCor Advanced System improve symptoms of osteoarthritis?

Researchers will compare range of motion measurements, sit to stand test results, and functional survey answers to see if there are any changes after 4 weeks of therapy with the OrthoCor Advanced System.

Participants will use the OrthoCor Active System for 30 minutes twice daily and complete recovery measurements daily using an application.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Osteoarthritis is a chronic condition characterized by degeneration of the joints, affecting up to 240 million people worldwide.1 Its disabling effects are frequently associated with persistent joint pain, loss of mobility and function, and decreased quality of life that often lead to surgical procedures such as partial or total joint arthroplasty.1 Pulsed Electromagnetic Field (PEMF) therapy is a safe, clinically proven, nonpharmacological therapy that has previously been shown to have beneficial effects on pain and physical function in patients with osteoarthritis.1,2 The OrthoCor Advanced System's novel combination of PEMF with the ability to monitor mobility metrics may have additional beneficial effects on pain, function, and quality of life for individuals affected by osteoarthritis.

PEMF is a low-level, time-varying electromagnetic field that passes through and affects superficial soft tissue, helping to accelerate the body's natural anti-inflammatory and recovery responses. PEMF has been shown to stimulate tissue repair pathways that result in pain and inflammation reduction, such as the binding of calcium (Ca2+) to calmodulin (CaM) which triggers an anti-inflammatory nitric oxide (NO) cascade.2-4 NO is a key element in the body's natural healing process. It is also a vasodilator, increasing blood and lymphatic flow.3 Additionally, NO down-regulates interleukin-1 beta (IL1β) and inducible nitric oxide synthase (iNOS), which leads to reduced cyclooxygenase-2 (COX-2) activation and fewer prostaglandins - molecules responsible for causing inflammation and pain.5 Unlike other systemic COX-2 inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), OrthoCor's targeted PEMF signals locally modify these pathways, thereby reducing pain and inflammation without the risks and side effects associated with systemic medication.5

In addition to applying PEMF therapy, the OrthoCor Advanced System features a consumer facing smart device application as well as prescriber portal, allowing direct visibility of therapy compliance, reported pain levels, and functional performance metrics by both patient and physician. Daily recovery measurements may additionally supplement range of motion and joint strengthening and may encourage daily adherence to prescribed physical therapy and exercise. Strengthening exercises are considered a core standard of care treatment for managing knee osteoarthritis.5 Thus, the combined effects of PEMF and recovery insights may provide enhanced benefits to affected patients.

The OrthoCor Advanced System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy plus chemical heat from OrthoPods for pain relief in the ankle, back, knee, wrist, elbow, shoulder, foot, or neck, while also providing the user with functional and mobility metrics. The microprocessor delivers the pulsed RF signal to the tissue target via inductive coupling with an applicator coil, while a 9-axis motion sensor tracks joint mobility during therapy.

The objective of this study is to evaluate the effectiveness of the OrthoCor Advanced System device for relieving symptoms and improving physical function in patients with osteoarthritis of the knee. It is hypothesized that the OrthoCor Advanced System device will improve knee range of motion and reported quality of life, as well as decrease reported pain levels associated with the knee.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Gulf Breeze, Florida, United States, 32561
        • Andrews Research & Education Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Presenting to the study site with knee pain for at least 3 months, with articular cartilage loss confirmed by imaging study
  2. An initial pain VAS score >4
  3. At least 2 hours of daily standing and/or walking activity
  4. Prescribed use of the OrthoCor Advanced System
  5. Daily access to a smartphone or tablet compatible with the OrthoCor Medical application
  6. Able to download and install app to smart phone
  7. Willing and able to provide written consent
  8. ≥18 years of age

Exclusion Criteria:

  1. Previous diagnosis of rheumatoid arthritis or gout
  2. Cortisone injection, knee surgery, or viscosupplementation in the previous 6 months
  3. Prior knee replacement
  4. Have a cardiac pacemaker, cardioverter defibrillator, neurostimulator, infusion pump or any active medical implant
  5. Have an implanted metallic lead or any type of wire coil implant, or any implanted system that may contain a lead
  6. Known or expected pregnancy
  7. Have an open wound at the area of application
  8. Are not able to sense or not fully aware of the sensation of heat
  9. Have poor circulation or heart disease
  10. Have uncontrolled diabetes
  11. Under the age of 18 or individuals with open bone growth plates
  12. Unwilling or unable to provide written consent
  13. Unwilling or unable to use the OrthoCor Advanced System
  14. Unwilling or unable to complete the pain assessment survey
  15. Enrolled in a study to evaluate an investigational drug
  16. Prisoner or under incarceration

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: OrthoCor Advanced System
The OrthoCor Advanced System's novel combination of PEMF with the ability to monitor mobility metrics may have additional beneficial effects on pain, function, and quality of life for individuals affected by osteoarthritis.
The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events
Time Frame: during 4 weeks of treatment
Primary Safety Endpoint: Number of Adverse Events
during 4 weeks of treatment
VAS pain score
Time Frame: before, during, and after 4 weeks of treatment
Primary Efficacy Endpoint: Pain score from 0-10 on the Visual Analog pain Scale (VAS), with 0 indicating no pain and 10 indicating the worst pain imaginable
before, during, and after 4 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knee AROM
Time Frame: before and after 4 weeks of treatment
Active Range of Motion (AROM) for the Knee
before and after 4 weeks of treatment
Sit-to-stand
Time Frame: before and after 4 weeks of treatment
Number of times in 30 seconds patient can perform sit-to-stand motion
before and after 4 weeks of treatment
Pain medication use
Time Frame: during 4 weeks of treatment
Daily recording of pain medication taken
during 4 weeks of treatment
Joint motion tracking
Time Frame: during 4 weeks of treatment
Joint motion tracking data recorded by the application during daily recovery exercises
during 4 weeks of treatment
KOOS survey
Time Frame: before and after 4 weeks of treatment
Knee injury and Osteoarthritis Outcome Score (KOOS) survey, from 0-100% with 0% indicating the worst function possible and 100% indicating full function
before and after 4 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joshua G Hackel, MD, The Andrews Research & Education Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2024

Primary Completion (Actual)

October 6, 2025

Study Completion (Actual)

October 6, 2025

Study Registration Dates

First Submitted

June 21, 2024

First Submitted That Met QC Criteria

June 21, 2024

First Posted (Actual)

June 26, 2024

Study Record Updates

Last Update Posted (Actual)

December 17, 2025

Last Update Submitted That Met QC Criteria

December 16, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on OrthoCor Advanced System

Subscribe